Counties where doctors got more meals, trips and consulting fees from opioid makers had higher overdose deaths involving prescription opioids.
JTThe underlying @JAMA_current paper is so bad I dont know how to write a critique.
The core problem is that they apparently made up the data.
WTF is a regression analysis on "imputed data" anyway?
Drug Alcohol Depend. 2018 Oct 25;194:151-158. doi: 10.1016/j.drugalcdep.2018.09.019. [Epub ahead of print]
JTInteresting Canadian medical records study of opiate overdoses
9,964 pts died or were seen in ER for opiate overdose in 2015, of which
<10% had an active opioid Rx at time of OD. <5% had multiple Rxs
Only 34% had received an opioid Rx within 5 years
There are more than 30 million Americans with diabetes, a disease that costs the U.S. more than $327 billion per year (1,2). Achieving glycemic control and controlling cardiovascular risk factors have been conclusively shown to reduce diabetes...
JTThe article further noted that the price of Humalog had risen by 138% over a 6 year period, but only 6% of that increase went to Lilly. care.diabetesjournals.org/content/41/6/1…
In general it seems to me that before going on a moral crusade, it would be a good idea to read up on the data.
New York’s Medicaid program says Orkambi, a new drug to treat cystic fibrosis, is not worth the price. The case is being closely watched around the country.
JT@DavidP4AD@VertexPharma@P4AD_ I don't know who Axios is David. Multiple other sources place compensation $51M below your figure
Per the NYTimes, she is only $3K short. You're accusing Vertex of letting her die because of greed. But they've put in $5.1B. Why not write her a check?
Updated world stock indexes. Get an overview of major world indexes, current values and stock market data.
JT@DavidP4AD@VertexPharma o I believe you are off on the compensation package by about $51M bloomberg.com/research/stock… …
o If you feel that strongly about it, why not pay for the drugs yourself? Vertex has already done more for CF patients than any person or organization in history
Tracking retractions as a window into the scientific process
JT@RogueRad@barttels2@Rfonsi1@NickBudnick Naah. Let's worry about things that we can demonstrate have negative effects that outweigh their positive effects.
Like the competition for tenure, grants, and notoriety.
“History is repeating itself with hepatitis C –the medicines we need are again too expensive, but we are finding ways to make treatment affordable so that our patients can be cured.”
JTThis BTW, is an extraordinary PR from Medicines san Frontiers. Blasts $GILD for high sofosbuvir prices, then congratulate selves for making available at lower price. But at lower price was due to $GILD licensing IP to generic cos for developing world.
JT@BERector@DrPaulyDeSantis So "almost half" went to a distributor who took no risk, spent no development money, and basically served as a distribution intermediary?
And the company that developed the drug, including 585 clinicaltrials.gov listed studies, took "more than half"?